September 2025 Novartis received U.S. FDA approval for remibrutinib, a first-in-class oral Bruton's tyrosine kinase (BTK) inhibitor, for adults with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1-antihistamine treatment. The approval introduced a novel targeted oral treatment option that complements conventional antihistamine therapy for difficult-to-treat patients.
May 2025 Glenmark Specialty received approval from China’s National Medical Products Administration (NMPA) for Ryaltris® (olopatadine hydrochloride and mometasone furoate nasal spray) for the treatment of allergic rhinitis in adults and children. Under its existing licensing agreement, Grand Pharmaceutical Group will commercialize the product in China, expanding access to combination antihistamine therapy in one of the world's largest allergy treatment markets.